STADA and Walmark to join forces in Romania

Mihai Cristea 06/03/2020 | 16:52

STADA Romania, the Romanian subsidiary of STADA Arzneimittel AG, announces the beginning of the integration process of Walmark Romania, aiming to become one of the fastest-growing pharmaceutical companies on the Romanian market, with a portfolio of RX and OTC products.

 

STADA Romania – Key figures

Stada Romania estimates an increase of more than 20% in turnover for 2019.

The increase is due to both the expansion of the product portfolio as well as the development of the team.

For 2020, STADA Romania (Stada M&D SRL) estimates double-digit growth maintaining the growth rate of the previous year. The budgeted growth is expected to come mainly from the development of the product portfolio, including the integration of 3 out of the 15 products purchased globally earlier this year by STADA Arzneimittel AG from GSK (CeTeBe, Orofar, Duofilm). In support of sales and marketing activities, STADA Romania is also running modern logistic operations that will be relocated in a new modern warehouse located in Timis county, that will function as a hub for the whole territory of Romania.

2020 is going to be a truly transformational year when Stada will become substantially stronger in Romania with focus on integrating the local operations of Walmark Romania, a transaction that took place globally at the end of 2019 and was approved locally by the Competition Council on February 19.

On November 4, 2019, STADA Arzneimittel AG announced that it had taken over Walmark a.s. from the investment fund Mid Europa Partners, pursuing in this way its objective, to be one of the largest pharmaceutical groups of generic drugs and CHC (non-prescription) products globally, to strengthen the portfolio in the Consumer Health segment and to consolidate the business on Eastern European markets.

The integration of the operations of Walmark Romania will be done gradually, during the whole year, through a detailed analysis of its performances, at local level. The analysis will include both the performance of retail products, as well as the performance of employees and their alignment with STADA integrity values and policies, as well as national logistics and distribution operations.

Walmark includes in its product portfolio over 1000 references, vitamins and food supplements well established in all nine markets that is present (Czech Republic, Slovakia, Poland, Hungary, Romania, Bulgaria, Lithuania, Latvia and Estonia), with an extended addressability, from children to the elderly. Its portfolio includes products such as Minimartians (vitamins for children), Prostenal (adjuvant in men health), Urinal (urinary tract health), Beliema (women health), Sinulan (respiratory tract).

“This year will be a very important year for STADA Romania, with a lot of opportunities to become stronger and accelerate growth. We have a huge responsibility to integrate Walmark Romania and to align the new team of over 70 people with STADA values, to integrate GSK products present in our local market into the Stada portfolio, but also to relocate the Timis warehouse. And above all, we have the responsibility to launch new products, even innovative ones, for Romanian patients, to help them in their therapies. I am convinced, however, that the new team that will be formed, will successfully face these challenges and also, that all together, will be able to be as successful, occupying next year a leading position in the top 10 pharmaceutical companies in Romania.” stated Dr. Mihai Fugarevici, Country Manager STADA Romania.

“We are committed to invest and grow in Romania. The combination of Stada and Walmark will make us stronger in Romania and creates opportunities for accelerated business growth. Stada and Walmark have strong brands in their portfolios and I trust our combined Romanian team under the lead of Mihai Fugarevici will achieve great results.“ said Dr. Steffen Wagner, Head of European Markets at the STADA Group.

 

Close ×

We use cookies for keeping our website reliable and secure, personalising content and ads, providing social media features and to analyse how our website is used.

Accept & continue